Últimas noticias sobre Apyx Medical (NASDAQ:APYX) Bolsa

Apyx Medical

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Bovie Medical

Apyx Medical Corp

Iamgold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 1900 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $438.900 million which missed the analyst consensus estimate of $438.910 million by 0 percent. This is a 95.50 percent increase over sales of $224.500 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Iamgold Q3 2024 Adj. EPS $0.18 Beats $0.10 Estimate, Sales $438.900M Miss $438.910M Estimate

Orion Office REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONL#NYSE">ONL</a>) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. The company reported quarterly sales of $38.976 million which beat the analyst consensus estimate of $38.500 million by 1.24 percent. This is a 20.26 percent decrease over sales of $48.876 million the same period last year.

Orion Office REIT Q3 2024 FFO $0.21, Inline, Sales $38.976M Beat $38.500M Estimate

Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.46 by 13.04 percent. The company reported quarterly sales of $26.498 million which missed the analyst consensus estimate of $27.355 million by 3.13 percent. This is a 2.46 percent decrease over sales of $27.165 million the same period last year.

Stellus Cap Investment Q3 2024 Adj. EPS $0.40 Misses $0.46 Estimate, Sales $26.498M Miss $27.355M Estimate

Pitney Bowes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.14 by 50 percent. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $499.463 million which beat the analyst consensus estimate of $467.802 million by 6.77 percent. This is a 0.71 percent decrease over sales of $503.033 million the same period last year.

Pitney Bowes Q3 2024 Adj. EPS $0.21 Beats $0.14 Estimate, Sales $499.463M Beat $467.802M Estimate

Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.48 by 2.08 percent. This is a 27.03 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $55.857 million which beat the analyst consensus estimate of $53.900 million by 3.63 percent. This is a 25.32 percent increase over sales of $44.573 million the same period last year.

Velocity Financial Q3 2024 Adj. EPS $0.47 Misses $0.48 Estimate, Sales $55.857M Beat $53.900M Estimate

Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.69) by 4.35 percent. This is a 1.37 percent increase over losses of $(0.73) per share from the same period last year.

RLMD

Relmada Therapeutics Q3 2024 GAAP EPS $(0.72) Misses $(0.69) Estimate

<h3 class="wp-block-heading">Ispire Technology</h3>
Ispire Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) will host its earnings conference call at 8:00 am Eastern Time on Tuesday, Nov. 12, 2024, to discuss the company&#8217;s financial results for its fiscal first quarter ended Sept. 30, 2024.
According to Michael Wang, the company&#8217;s co-CEO, 2024 was "a foundational year for Ispire." The company <a href="https://www.benzinga.com/markets/cannabis/24/09/41049463/nasdaq-listed-vaping-company-ispire-reports-31-yoy-increase-in-2024-revenue">reported</a> record revenue and substantial margin expansion while &#8220;strategically positioning us for faster growth in our global nicotine business and intentionally focusing our cannabis vaping hardware on high-quality multi-state operator (MSO) customers,&#8221; Wang continued.
Revenue increased 31.4% year-over-year to $151.9 million as compared to $115.6 million in the 2023 fiscal year.
During an interview on Benzinga&#8217;s Cannabis Insider <a href="https://www.benzinga.com/topic/cannabis-insider">podcast</a> earlier this year Wang said that &#8220;vaping will become the number one way for using <a href="https://www.benzinga.com/markets/cannabis/24/06/39291319/exclusive-ispires-ceo-michael-wang-predicts-vaping-will-soon-surpass-cannabis-flower-sales">cannabis within the next 2 or 3 years.&#8221;</a>
Ispire's shares traded 5.56% lower at $6.12 per share at the time of writing on Thursday.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/39049831/cannabis-vape-tech-producer-ispire-enters-south-african-market-via-exclusive-deal-with-dank-pack">Cannabis Vape Tech Producer Ispire Enters South African Market Via Exclusive Deal With Dank Pack</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Gold Flora</h3>
Vertically-integrated California cannabis company Gold Flora Corporation (Cboe Canada: GRAM) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/GRAM#OTCQB">GRAM</a>) will report financial results on Thursday, Nov. 14 for the third quarter ended Sept. 30, 2024. The company will host a conference call to discuss the results at 6:00 pm Eastern Time, on the same day.
The second quarter earnings report made public in August revealed $31.64 million in revenue for the period, reflecting a slight decrease of 2% from the previous quarter. Gross profit dropped significantly by 28%, totaling $7.25 million in the second quarter, <a href="https://www.benzinga.com/markets/cannabis/24/08/40401702/gold-flora-q2-earnings-revenue-soars-though-net-loss-widens-to-24m">resulting in a gross margin of 23%.</a>
In October, Gold Flora&#8217;s common shares were approved to quote on the OTC Market&#8217;s Group Inc.&#8217;s OTCQB Venture Market in the U.S. under the ticker symbol &#8220;GRAM."
<h3 class="wp-block-heading">Vext Science</h3>
Vext Science, Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/VEXT#CSE">VEXT</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VEXTF#OTCQX">VEXTF</a>) a U.S.-based cannabis operator with vertical operations in Arizona and Ohio plans to release its financial results before the market opens on Nov. 21 for the third quarter ending Sept. 30, 2024, The earnings conference call and webcast will take place on the same day at 08:00 am Eastern Time.
Pablo Zuanic, senior analyst at Zuanic &amp; Associates initiated coverage of Vext Science with an Overweight rating earlier this year, highlighting the company's significant growth potential.
As highlighted by Benzinga&#8217;s <a href="https://www.benzinga.com/author/nicol-s-jose-rodriguez">Nicolás Jose Rodriguez</a>, Zuanic calculated that Vext has the most EBITDA torque among the twelve public multi-state operators (MSOs) in Ohio, projecting Vext's EBITDA could grow six-fold by calendar 2026, taking calendar 2023 as the base year. Recreational marijuana sales launched across Ohio on <a href="https://www.benzinga.com/markets/cannabis/24/08/40172821/its-official-ohio-begins-recreational-cannabis-sales-on-tuesday-heres-where-and-how-you-know-the">Tuesday, Aug. 6.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40761882/1b-in-26-days-this-marijuana-company-is-capitalizing-on-ohios-cannabis-surge">$1B In 26 Days: This Marijuana Company Is Capitalizing On Ohio&#8217;s Cannabis Surge</a></li>
</ul>

Cannabis

CSE:VEXT

GRAM

ISPR

VEXTF

Cannabis Co With Significant Growth Potential And Other Marijuana Operators Will Soon Report Earnings

Credicorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAP#NYSE">BAP</a>) reported quarterly earnings of $5.09 per share which beat the analyst consensus estimate of $4.57 by 11.38 percent. This is a 20.62 percent increase over earnings of $4.22 per share from the same period last year. The company reported quarterly sales of $1.39 billion which missed the analyst consensus estimate of $1.42 billion by 2.25 percent. This is a 9.38 percent increase over sales of $1.27 billion the same period last year.

Credicorp Q3 EPS $5.09 Beats $4.57 Estimate, Sales $1.39B Miss $1.42B Estimate

The Trade Desk Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) shares are falling after the company reported third-quarter financial results after the market close on Thursday. Here&#8217;s a <a href="https://www.benzinga.com/quote/TTD">rundown of the report</a>.
<ul>
<li>Q3 Revenue: $628 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $619.85 million</li>
</ul>
<ul>
<li>Q3 Adjusted EPS: 41 cents, versus estimates of 39 cents</li>
</ul>
The Trade Desk reported total revenue growth of 27% year-over-year and noted customer retention remained strong at over 95% in the third quarter.
&#8220;The Trade Desk delivered strong performance in the&nbsp;third quarter, with revenue of&nbsp;$628 million, accelerating growth to&nbsp;27%. This performance underlines the value that advertisers are placing on precision and transparency as they work with us to maximize the impact of their campaigns,&#8221; said Jeff Green, co-founder and CEO of The Trade Desk. 
&#8220;As we enter our busiest time of year and look ahead to 2025, we have never been in a better position to capture greater share of the&nbsp;$1 trillion&nbsp;advertising TAM.&#8221;
The company said it repurchased $54 million of its common stock in the quarter. The Trade Desk had $521 million remaining on its buyback as of Sept. 30. The company ended the quarter with $1.22 billion in cash and equivalents.
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/41826457/block-shares-sink-after-mixed-q3-results-eps-beat-revenues-miss">Block Shares Sink After Mixed Q3 Results: EPS Beat, Revenues Miss</a>
Guidance: The Trade Desk expects fourth-quarter revenue of at least $756 million, versus estimates of $749.78 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company expects fourth-quarter adjusted EBITDA of approximately $363 million.
&#8220;Many of the largest media companies are now working with us to help clients capture the full value of CTV advertising via programmatic. We are similarly excited about the momentum in retail media and the pace of adoption by advertisers who are taking advantage of our retail data marketplace. And the performance improvements that our clients are seeing with Kokai — our largest platform upgrade to date — showcase the value of audience-driven, AI-enabled innovation,&#8221; Green said.
TTD Price Action: The Trade Desk shares were down 10.10% in after hours, trading at $119.15 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Pixabay.

Guidance

Movers

The Trade Desk Stock Is Tumbling After The Bell: What's Going On?

CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 80.95 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $9.390 million which missed the analyst consensus estimate of $10.181 million by 7.77 percent. This is a 6.57 percent increase over sales of $8.811 million the same period last year.

CTSO

CytoSorbents Q3 2024 GAAP EPS $(0.04) Beats $(0.06) Estimate, Sales $9.390M Miss $10.181M Estimate

It is payable on Jan. 31, 2025 to shareholders of record at the close of business on Dec. 31, 2024.&nbsp;

Dividends

SOBO

South Bow Declares Its Inaugural Quarterly Dividend Of $0.50 Per Share

Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 400 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $72.77 million which missed the analyst consensus estimate of $77.09 million by 5.61 percent. This is a 3.32 percent increase over sales of $70.42 million the same period last year.

QRHC

CORRECTION: Quest Resource Holding Q3 Adj $(0.06) Misses $(0.01) Estimate, Sales $72.77M Miss $77.09M Estimate

Ziff Davis Reaffirms FY24 Guidance For Revenue Of $1.411B - $1.471B (Est $1.417B), Adjusted EPS Of $6.43 - $6.77 (Est $6.60)

Vacasa (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) reported quarterly earnings of $2.10 per share which missed the analyst consensus estimate of $2.37 by 11.39 percent. The company reported quarterly sales of $314.048 million which beat the analyst consensus estimate of $305.161 million by 2.91 percent. This is a 17.15 percent decrease over sales of $379.077 million the same period last year.

VCSA

Vacasa Q3 2024 GAAP EPS $2.10 Misses $2.37 Estimate, Sales $314.048M Beat $305.161M Estimate

Pitney Bowes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) .

Pitney Bowes expects FY2024 revenue to decline at a low-single-digit rate.

The expansion will add maintenance, repair and overhaul (MRO) capabilities for the Pratt &amp; Whitney GTF engine in New Zealand, with capacity for up to 140 GTF engine overhauls planned annually by 2032.

Pratt & Whitney, Air New Zealand Reveal $150M, 14,000 Square Meter Expansion Of Christchurch Engine Centre

Profound Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 46.15 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $2.832 million which missed the analyst consensus estimate of $3.006 million by 5.78 percent. This is a 63.89 percent increase over sales of $1.728 million the same period last year.

PROF

Profound Medical Q3 2024 GAAP EPS $(0.38) Misses $(0.30) Estimate, Sales $2.832M Miss $3.006M Estimate

Astrana Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) lowers FY2024 GAAP EPS guidance from $1.12-1.36 to $1.06-1.19 vs $1.31 analyst estimate. Raises FY2024 sales outlook from $1.75 billion-1.85 billion to $1.95 billion-2.03 billion vs $1.83 billion estimate.

ASTH

Astrana Health Lowers FY2024 GAAP EPS Guidance from $1.12-1.36 to $1.06-1.19 vs $1.31 Est; Raises FY2024 Sales Guidance from $1.75B-1.85B to $1.95B-2.03B vs $1.83B Est

Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.47 by 31.91 percent. This is a 20 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $500.873 million which beat the analyst consensus estimate of $482.859 million by 3.73 percent. This is a 49.45 percent increase over sales of $335.149 million the same period last year.

AMRC

Ameresco Q3 2024 Adj. EPS $0.32 Misses $0.47 Estimate, Sales $500.873M Beat $482.859M Estimate

Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) reported quarterly earnings of $1.64 per share which beat the analyst consensus estimate of $1.51 by 8.61 percent. This is a 9.33 percent increase over earnings of $1.50 per share from the same period last year. The company reported quarterly sales of $353.58 million which beat the analyst consensus estimate of $347.13 million by 1.86 percent. This is a 3.69 percent increase over sales of $340.99 million the same period last year.

Ziff Davis Q3 2024 Adj EPS $1.64 Beats $1.51 Estimate, Sales $353.58M Beat $347.13M Estimate

Apyx Medical GAAP EPS of -$0.19 beats by $0.01, revenue of $12.14M beats by $0.39M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Apyx Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/apyx-stock-quote/">APYX</a>) just reported results for the second quarter of 2024.<ul><li>Apyx Medical reported earnings per share of -19 cents. This was above the analyst estimate for EPS of -20 cents.</li><li>The company reported revenue of $12.15 million.</li><li>This was 3.40% better than the analyst estimate for revenue of $11.75 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/apyx-stock-earnings-apyx-medical-for-q2-of-2024/">APYX Stock Earnings: Apyx Medical Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

APYX Stock Earnings: Apyx Medical Beats EPS, Beats Revenue for Q2 2024

Apyx Medical (APYX) Receives a Hold from Piper Sandler

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Apyx Medical (APYX – Research Report), with a price target o...

Lake Street Sticks to Its Buy Rating for Apyx Medical (APYX)

Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript

In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Apyx Medical (APYX – Research Report). The company's shar...

JMP Securities Sticks to Their Hold Rating for Apyx Medical (APYX)

Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Apyx Medical (APYX – Research Report) today. The company's shares closed yesterday at $...

Apyx Medical (APYX) Gets a Buy from Craig-Hallum

InMode: A Deep Dive After Q3 Earnings

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apyx Medical (APYX – Research Report) and Delcath Sy...

Analysts Offer Insights on Healthcare Companies: Apyx Medical (APYX) and Delcath Systems (DCTH)

Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on Apyx Medical (APYX – Research Report) today. The company's shares closed last Friday at...

Apyx Medical (APYX) Receives a Buy from Craig-Hallum

AIRS

APYX

CUTR

DCTH

INMD

RVNC

Press Releases

Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users' Summit

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Apyx Medical Corporation Announces Board Leadership Transition

Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook

Apyx Medical Corporation Launches the "Renewing Lives" Give-Back Campaign Providing Treatments with Renuvion to Benefit Physical Appearance and Mental Health

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures

Comments

Apyx Medical

Noticias

Últimas noticias sobre Apyx Medical (NASDAQ:APYX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL